The identification of the hexanucleotide repeat expansion (HRE) GGGGCC (G4C2) in the non-coding region of the C9ORF72 gene as the most frequent genetic cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) has opened the path for advances in the knowledge and treatment of these disorders, which remain incurable. Recent evidence suggests that HRE RNA can cause gain-of-function neurotoxicity, but haploinsufficiency has also been hypothesized. In this review, we describe the recent developments in therapeutic targeting of the pathological expansion of C9ORF72 for ALS, FTD, and other neurodegenerative disorders. Three approaches are prominent: (1) an antisense oligonucleotides/RNA interference strategy; (2) using small compounds to counteract the toxic effects directly exerted by RNA derived from the repeat transcription (foci), by the translation of dipeptide repeat proteins (DPRs) from the repeated sequence, or by the sequestration of RNA-binding proteins from the C9ORF72 expansion; and (3) gene therapy, not only for silencing the toxic RNA/protein, but also for rescuing haploinsufficiency caused by the reduced transcription of the C9ORF72 coding sequence or by the diminished availability of RNA-binding proteins that are sequestered by RNA foci. Finally, with the perspective of clinical therapy, we discuss the most promising progress that has been achieved to date in the field.

Development of Therapeutics for C9ORF72 ALS/FTD-related disorders / M.S.C. Mis, S. Brajkovic, F. Tafuri, N. Bresolin, G.P. Comi, S. Corti. - In: MOLECULAR NEUROBIOLOGY. - ISSN 0893-7648. - (2016). [Epub ahead of print]

Development of Therapeutics for C9ORF72 ALS/FTD-related disorders

S. Brajkovic
Secondo
;
N. Bresolin;G.P. Comi
Penultimo
;
S. Corti
2016

Abstract

The identification of the hexanucleotide repeat expansion (HRE) GGGGCC (G4C2) in the non-coding region of the C9ORF72 gene as the most frequent genetic cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) has opened the path for advances in the knowledge and treatment of these disorders, which remain incurable. Recent evidence suggests that HRE RNA can cause gain-of-function neurotoxicity, but haploinsufficiency has also been hypothesized. In this review, we describe the recent developments in therapeutic targeting of the pathological expansion of C9ORF72 for ALS, FTD, and other neurodegenerative disorders. Three approaches are prominent: (1) an antisense oligonucleotides/RNA interference strategy; (2) using small compounds to counteract the toxic effects directly exerted by RNA derived from the repeat transcription (foci), by the translation of dipeptide repeat proteins (DPRs) from the repeated sequence, or by the sequestration of RNA-binding proteins from the C9ORF72 expansion; and (3) gene therapy, not only for silencing the toxic RNA/protein, but also for rescuing haploinsufficiency caused by the reduced transcription of the C9ORF72 coding sequence or by the diminished availability of RNA-binding proteins that are sequestered by RNA foci. Finally, with the perspective of clinical therapy, we discuss the most promising progress that has been achieved to date in the field.
Antisense oligonucleotides; Haploinsufficiency; Hexanucleotide repeat expansion
Settore MED/26 - Neurologia
Settore MED/03 - Genetica Medica
Settore BIO/18 - Genetica
28-giu-2016
Article (author)
File in questo prodotto:
File Dimensione Formato  
Development of Therapeutics for C9ORF72 2016 AIR version.pdf

accesso aperto

Descrizione: articolo principale
Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 538.64 kB
Formato Adobe PDF
538.64 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/419697
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 19
social impact